Depomed — Assertio Therapeutics — Investor Presentation (January 2019)
20 slides from Depomed's investor presentation, Jan 7, 2019
Slide 1: About this Presentation
About this Presentation The statements that are not historical facts contained in this presentation are forward-looking statements including, but not limited to, statements relating to the commercialization of Gralise, CAMBIA, and Zipsor, royalties associated with Collegium’s commercialization of NU
Slide 2: The "Old" Depomed: Primarily an Opioid-Based Company Prior to 2018
Past 3 The “Old” Depomed Primarily an Opioid-Based Company Prior to 2018 NUCYNTA and Lazanda franchises place Depomed with a heavy opioid concentration in a volatile market NUCYNTA 300 person field force needed to be downsized and retargeted with significant dislocation risk Promotionally-sensitive
Slide 3: Transformation Underway to Leaner, Faster-Moving, More Entrepreneurial Company
4 Transformation Underway to Leaner, Faster-Moving, More Entrepreneurial Company TRANSFORMATION: Exit Opioid Commercialization 2016 2018E # of Employees(1) ~500 ~120 Non-GAAP SG&A(2) $189 million $105 million(3) 2016 2017 2018 (1) Includes sales force. (2) Refer to Appendix for a reconciliation of a
Slide 4: New Name, Renewed Mission: Advance Patient Care in Neurology, Orphan & Specialty
New Name, Renewed Mission: Advance Patient Care in the Company’s Core Areas of Neurology, Orphan & Specialty Medicines 5 Assertio Therapeutics, Inc. (Assertio) is a new name that reflects a new business strategy, mission, vision and values A Company committed to putting patients first and creating s
Slide 5: A Clear Strategy for Growth
A Clear Strategy for Growth 6 Continued Execution of Three-Pillar Growth Strategy to Transform Company MAINTAIN a Strong/Profitable NUCYNTA® Franchise GROW Neurology Business BUILD a New Orphan/Specialty Business Amended and Strengthened Commercialization agreement with Collegium Pharmaceutical Stre
Slide 6: Collegium Partnership Supports Maintaining a Strong/Profitable NUCYNTA Franchise
Collegium Partnership Supports Maintaining a Strong/Profitable NUCYNTA® Franchise 7 MAINTAIN Original Contract As Amended $MM 4yrs; No Termination 2yrs; Term notice 1/1/19 4yrs Collegium Royalty Income $540 $270 $498.6(1) Upfront/Term Payment 10 35 10 Grünenthal Make Whole (18.4) (9.2) (4.6) Asserti
Slide 7: Growing our Neurology Business
Growing our Neurology Business A Portfolio with Extended Patent Exclusivity *Amended existing license agreement for a new presentation of Cambia which, if approved by FDA, may provide patent protection through at least 2026 ASSERTIO LAUNCH Q4 2011 Q2 2012 Q1 2014 INDICATIONS Management of postherpet
Slide 8: Growing Our Neurology Business
Growing Our Neurology Business 9 GROW Q3 ’18 stabilized core neurology brands with positive sequential total prescription growth for the franchise; but more work to do with Gralise® Q3 ’18 neurology product net sales increased $29.4 million, up 14 percent sequentially Q3 ‘18 began roll-out of new co
Slide 9: Building a Specialty / Orphan Business
Building a Specialty / Orphan Business Cosyntropin (synthetic ACTH depot) is First in a Portfolio of High-Value, High-Touch Orphan/Specialty Medicine Positioned to Address the Needs of Patients, Physicians and Payors 10 BUILD Filed for FDA approval of cosyntropin depot in Dec. 2018 1st Indication (d
Slide 10: Improving Capital Structure
Improving Capital Structure Current Secured Debt Payment Schedule Significantly De-levers Company 11 (1) Assumes mid-point of trailing 12-month adjusted EBITDA of $125 to $135; excludes PDL. $97 million in non-dilutive cash secured through transactions in 2018 combined with future operating cash flo
Slide 11: Milestones Achieved in 2018
Milestones Achieved in 2018 12 Synthetic cosyntropin (synthetic ACTH depot): Filed NDA in Dec. 2018 Amends and strengthens terms of Collegium Commercialization Agreement: Annual royalty payments secured through 2021 Agreement with PDL BioPharma to monetize royalty stream: Company received $20 millio
Slide 12: Third-Quarter 2018 Five Key Messages
13 Third-Quarter 2018 Five Key Messages 1. 2. 3. 4. 5. - Delivered a solid quarter - Continue to make excellent progress executing against 3-pillar strategy of Maintain, Grow & Build - Reaffirmed full-year guidance - Amended and strengthened Collegium agreement; eliminates any concern regarding earl
Slide 13: Full-Year 2018 Financial Guidance
Full-Year 2018 Financial Guidance 14 Prior 2018 Guidance Current 2018 Guidance Neurology Franchise Net Sales $105 to $110 million $105 to $110 million GAAP SG&A Expense $118 to $128 million $118 to $128 million GAAP R&D Expense $9 to $14 million $9 to $14 million Non-GAAP SG&A Expense $100 to $110 m
Slide 14: Full-Year 2018 Financial Guidance
Full-Year 2018 Financial Guidance Prior 2018 Guidance Current 2018 Guidance Neurology Franchise Net Sales $105 to $110 million $105 to $110 million GAAP SG&A Expense $118 to $128 million $118 to $128 million GAAP R&D Expense $9 to $14 million $9 to $14 million Non-GAAP SG&A Expense $100 to $110 mill
Slide 15: Note Regarding Use of GAAP and Non-GAAP Financial Measures
16 Note Regarding Use of GAAP and Non-GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (GAAP) basis, the Company has included information about non-GAAP revenue, non-GAAP adjusted earnings,
Slide 16: Non-GAAP Reconciliation
17 Non-GAAP Reconciliation (in millions) (unaudited)
Slide 17: Non-GAAP Reconciliation
18 Non-GAAP Reconciliation (in millions) (unaudited)
Slide 18: Full-Year 2018 Non-GAAP Guidance Reconciliation
19 Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited)
Slide 19: Full-Year 2018 Non-GAAP Guidance Reconciliation
Full-Year 2018 Non-GAAP Guidance Reconciliation (in millions) (unaudited) FULL-YEAR 2018 NON-GAAP GUIDANCE RECONCILATION Specified Items” So oMSS ous $ (1) GAAP net income guidance refers to GAAP net income and non-GAAP eamings guidance refers to non-GAAP adjusted (@) Fer purposes ofthis forward-loo
Slide 20: Assertio Therapeutics, January 2019
/SSSSERTIO= January 2019
Assertio Therapeutics — Investor Presentation (January 2019) on 6ix